Creso Pharma enters the sports market with cannabis based pain killer

15 March 2018, Written by David Simmons

Creso Pharma enters the sports market with cannabis based pain killer

Creso Pharma (ASX: CPH) has developed a new product range for the sports and osteoarthritis market addressing the need for muscle and join pain relief.

The product, called cannaDOL, is a cannabidiol-based oral nutraceutical that fulfils the demand for an organic and efficient product to relieve muscle and joint pain in sports people and osteoarthritis sufferers.

In addition to the oral product, Creso Pharma has produced a line of cosmetics under the cannaDOL name, made in partnership with the largest independent Swiss manufacturing group FRIKE Technologies.

The cannaDOL functional cosmetics product range follows a "dual action application concept" of cooling and heating which is formulated to promote the healing of injuries.

The cooling effect is generated by menthol whilst a combination of essential oils heat the targeted area to stimulate blood circulation and accelerate the healing process.

The oral product is a CBD-based food supplement which, according to Creso, aims to enhance collagen synthesis, fight fatigue and tiredness and stimulate metabolism.

The company says cannaDOL is aimed at people suffering from sports-related muscle injuries, arthritis and osteoarthritis.

The company initially plans to launch the product in the European market, which has a size of approximately EU$3.5 billion. The market is currently dominated by nonsteroidal anti-inflammatory drugs like ibuprofen, meaning there is a gap ready for customers looking for new organic natural treatment alternatives like cannaDOL.

Dr Miri Halperin Wernli, Creso Pharma CEO and co-founder, says the market is ready for a product like cannaDOL.

"People's perceptions of cannabis consumption have changed," says Wernli.

"Cannabis is no longer something to get high on. In the scientific community, CBD advocacy is on the rise, and evidence of its effectiveness across various health issues is growing. As cannabis legalisation spreads around the globe, a unique market, based on the health appeals of CBD, is emerging."

The cannaDOL product range is planned to be launched with commercial partners in the first half of 2019.

Never miss a news update, subscribe here. Follow us on Facebook, LinkedIn, Instagram and Twitter.

Business News Australia

Author: David Simmons





Contact us

Email News Update Sign Up Contact Details

PO Box 1487
Mudgeeraba QLD 4213

LoginTell a FriendSign Up to Newsletter